<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233216</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-019</org_study_id>
    <secondary_id>MK-8591A-019</secondary_id>
    <secondary_id>2019-000588-26</secondary_id>
    <secondary_id>205243</secondary_id>
    <nct_id>NCT04233216</nct_id>
  </id_info>
  <brief_title>Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)</brief_title>
  <official_title>A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and
      safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC)
      of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with
      human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage
      of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid
      (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination
      with failing antiretroviral therapy (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of this study (Day 1 to Day 7) is the double-blind period in which participants
      receive either ISL, DOR, DOR/ISL, or placebo. Part 2 of this study (Day 8 to Week 49) is the
      open-label period in which all participants receive DOR/ISL + optimized background therapy
      (OBT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants receiving doravirine/islatravir (DOR/ISL) with ≥0.5 log10 decrease from baseline in human immunodificiency virus type 1 (HIV-1) ribonucleic acid (RNA) compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The change from baseline in HIV-1 RNA will be determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 49 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants withdrawing from study treatment due to AE(s)</measure>
    <time_frame>Up to 49 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR or ISL (given with antiretoviral therapy [ART]) with ≥0.5 log10 decrease in HIV-1 RNA compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART), DOR, or ISL compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART), DOR, or ISL with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to placebo treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Day 8</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥0.5 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with ≥0.5 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with ≥1.0 log10 decrease from baseline in HIV-1 RNA compared to DOR or ISL treatment</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with ≥1.0 log10 change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) + OBT</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HIV-1 RNA following treatment with DOR/ISL (given with ART) + OBT</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The mean change from baseline in HIV-1 RNA will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;200 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;200 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;200 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;50 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;50 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;50 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;40 copies mL</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving DOR/ISL (given with ART) + OBT with HIV-1 RNA &lt;40 copies mL</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt;40 copies mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to DOR</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to DOR will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to DOR</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to DOR will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to ISL</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to ISL will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to ISL</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to ISL will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to optimized background therapy (OBT) components</measure>
    <time_frame>Week 25</time_frame>
    <description>The prevalence of viral drug resistance to OBT components will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of viral drug resistance to OBT components</measure>
    <time_frame>Week 49</time_frame>
    <description>The prevalence of viral drug resistance to OBT components will be determined. Viral resistance testing will be performed by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on viral resistance-associated substitutions (RASs)</measure>
    <time_frame>Day 1 (baseline) and Week 25</time_frame>
    <description>The role of baseline antiviral resistance on viral RAS will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on viral RASs</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The role of baseline antiviral resistance on viral RAS will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on HIV-1 RNA</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The role of baseline antiviral resistance on HIV-1 RNA will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of baseline antiviral resistance on HIV-1 RNA</measure>
    <time_frame>Day 8 (baseline) and Week 49</time_frame>
    <description>The role of baseline antiviral resistance on HIV-1 RNA will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 25</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 1 (baseline) and Week 49</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 8 (baseline) and Week 25</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell counts</measure>
    <time_frame>Day 8 (baseline) and Week 49</time_frame>
    <description>The change from baseline in CD4+ T-cell counts will be determined. CD4+ T-cell counts will be determined by the central laboratory.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Part 1, Group 1: ISL + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 2: DOR + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 3: DOR/ISL + ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 5: Open-Label DOR/ISL + OBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTE participants from Groups 1 to 4 with HIV-1 infection take open-label 100 mg DOR/0.75 mg ISL + OBT in Part 2 (Day 8 to Week 49).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISL</intervention_name>
    <description>ISL 0.75 mg capsule taken by mouth.</description>
    <arm_group_label>Part 1, Group 1: ISL + ART</arm_group_label>
    <other_name>Islatravir</other_name>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR</intervention_name>
    <description>DOR 100 mg tablet taken by mouth.</description>
    <arm_group_label>Part 1, Group 2: DOR + ART</arm_group_label>
    <other_name>Doravirine</other_name>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR/ISL</intervention_name>
    <description>100 mg DOR/0.75 mg ISL FDC taken by mouth.</description>
    <arm_group_label>Part 1, Group 3: DOR/ISL + ART</arm_group_label>
    <arm_group_label>Part 2, Group 5: Open-Label DOR/ISL + OBT</arm_group_label>
    <other_name>Doravirine/Islatravir</other_name>
    <other_name>MK-8591A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ISL</intervention_name>
    <description>Placebo capsule matched to ISL taken by mouth.</description>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to DOR</intervention_name>
    <description>Placebo tablet matched to DOR taken by mouth.</description>
    <arm_group_label>Part 1, Group 4: Placebo + ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is HIV-1 positive.

          -  Has been receiving the same baseline ART for ≥3 months prior to signing the Informed
             Consent Form/Assent Form.

          -  Weighs ≥35 kg.

          -  Has at least triple-class resistance (nucleoside reverse transcriptase inhibitor
             [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], and resistance to at
             least 1 other class [i.e., resistance to at least 1 drug in each class]) based on
             resistance testing at the Screening Visit.

          -  Has ≤1 fully active antiretroviral remaining that can be effectively combined to form
             a viable regimen based on resistance, tolerability, safety, drug access, or
             acceptability to participant.

          -  If female, is not pregnant or breastfeeding, and is: 1) not a woman of childbearing
             potential (WOCBP); 2) a WOCBP and uses an acceptable method of contraception/is
             abstinent; or 3) a WOCBP and has a negative pregnancy test within 24 hours of the
             first dose of study medication.

        Exclusion Criteria:

          -  Has HIV type 2 (HIV-2) infection.

          -  Has hypersensitivity or other contraindication to any of the components of the study
             interventions as determined by the investigator.

          -  Has hepatitis B virus (HBV) co-infection (defined as hepatitis B surface antigen
             [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive) and is not currently
             being treated for HBV.

          -  Has a history or current evidence of any condition, therapy (including active TB
             co-infection), laboratory abnormality or other circumstance (including drug or alcohol
             abuse or dependence) that might, in the opinion of the investigator, confound the
             results of the study or interfere with study participation for the full study
             duration.

          -  Is taking or is anticipated to require any of the prohibited therapies from the
             Screening Visit and throughout the study treatment period.

          -  Is taking DOR as part of his/her current failing antiretroviral regimen.

          -  Is taking efavirenz (EFV), etravirine, or nevirapine.

          -  Is currently participating in or has participated in an interventional clinical study
             with an investigational compound or device from the Screening Visit through the study
             treatment period.

          -  Is female and is expecting to conceive or donate eggs at any time during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Men's Health Foundation ( Site 4018)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>80069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-550-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc. ( Site 4016)</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>760-778-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine ( Site 4007)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-689-5191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital ( Site 4015)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-0371</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group ( Site 4014)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-497-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 4012)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 4020)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department ( Site 4029)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>912-651-1978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northstar Healthcare ( Site 4004)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-296-2400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland ( Site 4023)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-706-3727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill ( Site 4026)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-843-9975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 4034)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-839-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, PA ( Site 4005)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-276-5618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Peter Shalit, MD ( Site 4002)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-624-1441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 5300)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61293317228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital ( Site 5309)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61283821111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 5312)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 7 3894 0794</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 4405)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56996420376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arriaran ( Site 4401)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998205294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Cardiosur ( Site 4407)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8910259</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56963108092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 4301)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573155614943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital Archet 1 ( Site 4703)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33413423423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Marseille ( Site 4717)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33413423423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux- Hopital Saint Andre ( Site 4715)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hopital Saint-Eloi ( Site 4721)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467337220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 4700)</name>
      <address>
        <city>Tourcoing</city>
        <state>Nord</state>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320694617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen ( Site 4705)</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33232888739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu [Paris, France] ( Site 4723)</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142348836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 4714)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 4724)</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover ( Site 4612)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495115325155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn ( Site 4600)</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49222815421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen ( Site 4607)</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492017233878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 4603)</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930233212870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICH Study Center GmbH &amp; Co.KG ( Site 4609)</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+494028407370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita' Vita Salute. Ospedale San Raffaele ( Site 5002)</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390226437934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli-Ospedale Sacco ( Site 5000)</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390239043490</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 5006)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine ( Site 5401)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81332027181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital ( Site 5503)</name>
      <address>
        <city>Busan</city>
        <state>Pusan-Kwangyokshi</state>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82512407673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 5500)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222281974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 5502)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222586002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Via Libre ( Site 4500)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51944817657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Center for Prophylactic of AIDS and Inf. Diseases ( Site 5101)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast'</state>
        <zip>190020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124959976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Clinical Hospital #2 ( Site 5114)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79037143865</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 5100)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124644340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Center On Aids And Infectious Diseases Prophylaxis ( Site 5115)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast'</state>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74812219616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 5104)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78432678117</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4'-ethynyl-2-fluoro-2'-deoxyadenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

